UC BON.CAP.CERT. 09/24 FRE/ DE000HD397M4 /
8/30/2024 9:47:09 PM | Chg.0.000 | Bid9:59:07 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
37.970EUR | 0.00% | 37.940 Bid Size: 1,000 |
- Ask Size: - |
FRESENIUS SE+CO.KGAA... | - - | 9/27/2024 | Call |
GlobeNewswire
4/23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
2/25/2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
1/5/2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
12/31/2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
12/9/2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
11/12/2021
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights